Treatment sequences and survival outcomes in advanced HR + HER2- breast cancer patients: a real-world cohort

Breast Cancer Research and Treatment, Journal Year: 2024, Volume and Issue: 210(1), P. 115 - 124

Published: Nov. 7, 2024

Palliative treatment options for HR + HER2- advanced breast cancer (ABC) patients have increased, but data is lacking about the optimal sequence. We used real-world from a comprehensive center to describe applied sequences and we determined treatment-related survival outcomes. Patients aged 18 years older with ABC treated systemic were included in this historic cohort study. Sequential schedules, time discontinuation, chemotherapy, overall (OS) determined, stratified by first-line treatment. 202 included. They received total of 650 lines (median 3; range: 1-11). 91 (45%), 25 (12%), 24 28 (14%), 22 (11%) 12 (6%) started non-steroidal aromatase inhibitors (NSAI), NSAI cyclin dependent kinase 4/6-inhibitors (CDK4/6i), fulvestrant CDK4/6i, tamoxifen, chemotherapy other treatment, respectively. 10, 13, 14 different regimens given first, second third-line, Of who monotherapy (n = 91), 3 (3%) died before receiving second-line In cohort, observed wide variety daily clinical practice, some which discordance current guidelines. Fear that may never get around CDK4/6i if patient did not start was supported our study results.

Language: Английский

Anti-Breast Cancer Potential of New Indole Derivatives: Synthesis, In-Silico Study, and Cytotoxicity Evaluation on MCF-7 Cells

Journal of Molecular Structure, Journal Year: 2024, Volume and Issue: unknown, P. 141176 - 141176

Published: Dec. 1, 2024

Language: Английский